Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs NIO Inc. (NIO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs NIO Inc. — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $298.3 (market cap $8.04B), while NIO Inc. trades at $5.03 (market cap $12.99B). The key difference: NIO Inc. is the larger of the two by market cap, and Bio-Rad Laboratories, Inc. Class A Common Stock is trading nearer its 52-week high, NIO Inc. nearer its low. Which is the better fit depends on your goals.
| BIO | NIO | |
|---|---|---|
Market Cap | $8.04B | $12.99B |
Sector | Health | Consumer Cyclical |
52-Week High | $339.75 | $7.89 |
52-Week Low | $241.71 | $4.11 |
Enterprise Value | $7.85B | $12.22B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
NIO trades at $4.93, up 3.14% today, but remains in a bearish technical trend with negative cash flows and persistent losses despite revenue growth to $87.49 billion in 2025. The company beat EPS estimates for three consecutive quarters, and June 2026 deliveries surged 62.9% year-over-year, indicating strong operational momentum. However, net income margin improved to -17.8% in 2025 but remains deep in negative territory, with a high debt load and substantial cash burn from operations.
Outlook is mixed: bullish delivery growth and analyst upgrades (Goldman Sachs to Buy, target $7) contrast with profitability risks and competitive EV market pressures. Investment appeal hinges on margin improvement and sustainable cash flow generation, while key risks include execution challenges, macroeconomic headwinds, and reliance on financing amid negative equity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About NIO Inc.
NIO Inc. manufactures and sells automobiles. The Company offers electric vehicles and parts, as well as provides battery charging services. NIO serves customers worldwide.
Read more on NIO →
